Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis

Keywords

• Disease Progression
• Humans
• *Latent Tuberculosis
• *Tuberculosis
• Copenhagen, Denmark, outside the submitted work. In addition, he has patent
• WO2017084671A1 pending and patent WO2008028489A2 issued, and he has further
• served as Industry Representative at the Technical Expert Consultations
• supporting the development of the TPP for predictive tests. In January 2017, SSI
• divested the production of RT-23 purified protein derivative (PPD) for the TST to
• AJ Vaccines, hereby eliminating a potential conflict of interest for the RT-23
• PPD TST. Conflict of interest: R. Diel reports receiving fees and/or travel
• reimbursement from Cellestis, Oxford Immunotec and Pharmore, and travel
• reimbursement for serving on an advisory board from Generium, outside the
• submitted work.